Search
Aripiprazole lauroxil
go.drugbank.com/drugs/DB14185ApprovedIt is a prodrug of [aripiprazole], which acts as a partial agonist at the D2 and 5-HT1A receptors, and as an antagonist at the 5-HT2A receptors [A34289]. … On July 2nd, a different formulation of aripiprazole lauroxil marketed as Aristada Initio was FDA-approved for immediate initiation of Aristada at any dose.
Gadoversetamide
go.drugbank.com/drugs/DB00538ApprovedGadoversetamide, marketed under the trade name OptiMARK, is a gadolinium compound used as a contrast agent in magnetic resonance imaging (MRI), particularly imaging of the brain, spine and liver.
Bevacizumab
go.drugbank.com/drugs/DB00112ApprovedInvestigational[A192939,A192837,A192891,A193275] VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target. … [A286054] This off-label practice was formalized with the approval of Lytenava (bevacizumab-vikg in the US; bevacizumab gamma in the EU/UK), the first ophthalmic formulation of bevacizumab developed specifically
Onasemnogene abeparvovec
go.drugbank.com/drugs/DB15528ApprovedInvestigationalDeveloped by AveXis, a Novartis company,[A187253] onasemnogene abeparvovec is commonly marketed as Zolgensma®, which is available as a single-dose intravenous infusion. … [A187250] As there is no cure for SMA, onasemnogene abeparvovec is a disease-modifying agent that decelerates the disease progression, improves motor function, and manages the symptoms.
Adapalene
go.drugbank.com/drugs/DB00210ApprovedInvestigational[A193518] Differin®, produced by Galderma Labs, was first granted FDA approval on May 31st, 1996, as a 0.1% adapalene topical solution. … [A193521] [Tazarotene] is more efficacious than adapalene but is designated as pregnancy category X and hence is contraindicated in pregnant women.
Ichthammol
go.drugbank.com/drugs/DB11341ApprovedIt is available in OTC products as an active ingredient for the treatment of skin disorders such as eczema, psoriasis and boils as it is thought to exhibit anti-inflammatory, antibacterial and antimycotic … Ichthammol is also referred to as ammonium bituminosulfonate or ammonium bituminosulphonate.
Dronabinol
go.drugbank.com/drugs/DB00470ApprovedIllicitInvestigationalDronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). … THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased
Chlormadinone acetate
go.drugbank.com/drugs/DB15903ApprovedWithdrawnIn the US, chlormadinone acetate was formerly marketed as a component of the combination drug products Estalor-21 and C-Quens.
Glucarpidase
go.drugbank.com/drugs/DB08898ApprovedInvestigational[L39865] It is marketed as VORAXAZE. … It prevents methotrexate toxicity in patients with renal dysfunction who are undergoing high-dose methotrexate treatment, as it provides an alternative non-renal pathway for methotrexate elimination.
Ticagrelor
go.drugbank.com/drugs/DB08816ApprovedInvestigational[A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. Ticagrelor was granted EMA approval on 3 December 2010.